Anderson, MD, MAS, an assistant professor of medicine from the University of Pittsburgh, clinical trials of several GLP-1 receptor agonists like semaglutide (Wegovy/Ozempic, Novo Nordisk) for weight loss included exclusion criteria of chronic medical and psychiatric conditions. However, [FDA] labeling does not restrict these treatments in these populations, they wrote in JAMA Internal Medicine
A total of 1500cc of fat was removed
Only subjects that started for the first time to use ALCAR (for a minimum period of 6 months) from January 1st, 2011 to April 30th, 2019 were included
Some patients lose a significant percentage of body weight
Bruce Zuraw will summarize key clinical considerations that practicing physicians must keep in mind when prescribing preventive therapies developed through clinical trials
Potential Benefits of Glutaryl for Detroit Patients Many patients explore Glutaryl as part of a wellness, recovery, or healthy-aging routine